{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:46:35Z","timestamp":1783464395429,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This is an unusual case of voltage gated calcium channel (VGCC) antibodies leading to two distinct and chronologically separated neurologic syndromes without the presence of an underlying neoplasm. Lambert Eaton Myasthenic Syndrome (LEMS) presented five years prior to cerebellar ataxia. Both LEMS and cerebellar ataxia were responsive to treatment, but not the same therapy. He was diagnosed with LEMS through history, exam, electromyography\/nerve conduction studies (EMG\/NCS) with repetitive nerve stimulation (RNS) and antibody testing. He was treated with 3,4 diaminopyridine (3,4 DAP) with an excellent response. Five years later, he developed acute ataxia. The patient required months of intensive and continued immunomodulating therapy.<\/jats:p>","DOI":"10.1186\/s12883-024-03983-8","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T01:18:57Z","timestamp":1735780737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Late onset cerebellar ataxia syndrome after non-paraneoplastic Lambert-Eaton myasthenic syndrome: a case study"],"prefix":"10.1186","volume":"25","author":[{"given":"David P.","family":"Randall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"issue":"7","key":"3983_CR1","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","volume":"29","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Maddison P, Sont JK, Wirtz PW, Hilton-Jones D, Klooster R, et al. Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29(7):902\u20138. https:\/\/doi.org\/10.1200\/JCO.2010.32.0440","journal-title":"J Clin Oncol"},{"issue":"1","key":"3983_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/mus.26079","volume":"58","author":"PA Ambrose","year":"2018","unstructured":"Ambrose PA, Maddison P. Lambert-Eaton myasthenic syndrome and cerebellar ataxia: is response to immunotherapy a clue to pathogenesis? Muscle Nerve. 2018;58(1):4\u20136. https:\/\/doi.org\/10.1002\/mus.26079","journal-title":"Muscle Nerve"},{"issue":"9","key":"3983_CR3","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1007\/s00415-017-8541-9","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser B, Eymard B, Datt J, Mantegazza R. Lambert\u2013Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol. 2017;264(9):1854\u201363.","journal-title":"J Neurol"},{"issue":"1\u20132","key":"3983_CR4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jns.2008.02.004","volume":"270","author":"PJ Lorenzoni","year":"2008","unstructured":"Lorenzoni PJ, Scola RH, Lang B, Kay CSK, Teive HAG, Kowacs PA, et al. Cerebellar ataxia in non-paraneoplastic Lambert\u2013Eaton myasthenic syndrome. J Neurol Sci. 2008;270(1\u20132):194\u20136.","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"3983_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jns.2013.10.031","volume":"336","author":"A Rigamonti","year":"2014","unstructured":"Rigamonti A, Lauria G, Stanzani L, Mantero V, Andreetta F, Salmaggi A. Non-paraneoplastic voltage-gated calcium channels antibody-mediated cerebellar ataxia responsive to IVIG treatment. J Neurol Sci. 2014;336(1\u20132):169\u201370.","journal-title":"J Neurol Sci"},{"key":"3983_CR6","doi-asserted-by":"crossref","unstructured":"Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ. Lambert-Eaton myasthenic syndrome. Neurologic Clinics. 2018 [cited 2019 Dec 8];36(2):379\u201394. https:\/\/www.neurologic.theclinics.com\/article\/S0733-8619(18)30008-2\/abstract","DOI":"10.1016\/j.ncl.2018.01.008"},{"key":"3983_CR7","doi-asserted-by":"crossref","unstructured":"Bekircan-Kurt CE, Derle \u00c7ift\u00e7i E, Kurne AT, Anlar B. Voltage gated calcium channel antibody-related neurological diseases. World Journal of Clinical Cases: WJCC. 2015 [cited 2020 Mar 10];3(3):293\u2013300. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4360501\/","DOI":"10.12998\/wjcc.v3.i3.293"},{"issue":"3","key":"3983_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1590\/0004-282x20190020","volume":"77","author":"JL Pedroso","year":"2019","unstructured":"Pedroso JL, Vale TC, Braga-Neto P, Dutra LA, Fran\u00e7a MC Jr, Teive HAG, et al. Acute cerebellar ataxia: differential diagnosis and clinical approach. Arq Neuropsiquiatr. 2019;77(3):184\u201393.","journal-title":"Arq Neuropsiquiatr"},{"issue":"22","key":"3983_CR9","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","volume":"332","author":"VA Lennon","year":"1995","unstructured":"Lennon VA, Kryzer TJ, Griesmann GE, O\u2019Suilleabhain PE, Windebank AJ, Woppmann A, et al. Calcium-channel antibodies in the Lambert\u2013Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332(22):1467\u201375.","journal-title":"N Engl J Med"},{"key":"3983_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pediatrneurol.2016.06.004","volume":"62","author":"MC Spiciarich","year":"2016","unstructured":"Spiciarich MC, Mosh\u00e9 SL. Voltage-gated PQ-type calcium channel antibodies associated with cerebellar degeneration. Pediatr Neurol. 2016;62:43\u20136.","journal-title":"Pediatr Neurol"},{"key":"3983_CR11","volume-title":"Voltage-gated calcium channel autoimmune cerebellar degeneration","author":"M McKasson","year":"2016","unstructured":"McKasson M, Clardy SL, Clawson SA, Hill KE, Wood B, Carlson N, et al. Voltage-gated calcium channel autoimmune cerebellar degeneration. Neurol: Neuroimmunol Neuroinflamm; 2016;3(3)."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03983-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03983-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03983-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T02:03:53Z","timestamp":1735783433000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03983-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3983"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03983-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4945859\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained by the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient and his power of attorney provided written informed consent for personal and clinical details to be published in this paper. No identifying images were used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}